Amelioration of rodent type 2 diabetes by hemin has been linked to increased heme oxygenase (HO) activity, however alternative mechanisms have recently been proposed for its anti-diabetic effect. We sought to determine the anti-diabetic efficacy of heme arginate (HA), a clinically licensed preparation of heme, and whether its predominant mode of action is via increased HO activity. Intravenous administration of HA reduced hyperglycemia in diabetic (db/db) mice. Co-administration of the HO inhibitor stannous (IV) mesoporphyrin IX dichloride (SM) resulted unexpectedly in a further improvement in glycaemic control despite restoring HO activity to baseline levels. The anti-diabetic effects of HA±SM were associated with increased adiposity, increased serum adiponectin levels, reduced adipose tissue and islet inflammation and preservation of islet β-cell function. HO activity independent effects of HA on adipogenesis and β-cell inflammation were further confirmed in cell culture models using the 3T3-L1 pre-adipocyte and MIN6 β-cell lines, respectively. In conclusion, our work demonstrates that the heme component of HA ameliorates experimental type 2 diabetes by promoting metabolically favourable adipogenesis and preserving islet β-cell function, but this is not mediated via increased HO activity.
References
[1]
Yin L, Wu N, Curtin JC, Qatanani M, Szwergold NR, et al. (2007) Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways. Science 318: 1786–1789.
[2]
Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, et al. (2010) Regulation of adipogenesis by natural and synthetic REV–ERB ligands. Endocrinology 151: 3015–3025.
[3]
Ndisang JF, Jadhav A (2009) Up-regulating the hemeoxygenase system enhances insulin sensitivity and improves glucose metabolism in insulin-resistant diabetes in Goto-Kakizaki rats. Endocrinology 150: 2627–2636.
[4]
Ndisang JF, Lane N, Jadhav A (2009) The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways. Endocrinology 150: 2098–2108.
[5]
Ndisang JF, Lane N, Jadhav A (2009) Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 296: E1029–1041.
[6]
Grochot-Przeczek A, Dulak J, Jozkowicz A (2012) Haem oxygenase-1: non-canonical roles in physiology and pathology. Clin Sci (Lond) 122: 93–103.
[7]
Li M, Hyun Kim D, Tsenovoy PL, Peterson SJ, Rezzani R, et al.. (2008) Treatment of Obese Diabetic Mice with an Heme Oxygenase Inducer Reduces Visceral and Subcutaneous Adiposity, Increases Adiponectin Levels and Improves Insulin Sensitivity and Glucose Tolerance. Diabetes.
[8]
Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, et al. (2012) Regulation of circadian behaviour and metabolism by synthetic REV–ERB agonists. Nature 485: 62–68.
[9]
Tenhunen R, Tokola O, Lindén IB (1987) Haem arginate: a new stable haem compound. Journal of Pharmacy and Pharmacology 39: 780–786.
[10]
Tokola O, Tenhunen R, Volin L, Mustajoki P (1986) Pharmacokinetics of intravenously administered haem arginate. British journal of clinical pharmacology 22: 331–335.
[11]
McNally SJ, Ross JA, James Garden O, Wigmore SJ (2004) Optimization of the paired enzyme assay for heme oxygenase activity. Anal Biochem 332: 398–400.
[12]
Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA (2009) Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 24: 325–331.
[13]
Kato Y, Miura Y, Yamamoto N, Ozaki N, Oiso Y (2003) Suppressive effects of a selective inducible nitric oxide synthase (iNOS) inhibitor on pancreatic beta-cell dysfunction. Diabetologia 46: 1228–1233.
[14]
Huang JY, Chiang MT, Yet SF, Chau LY (2012) Myeloid heme oxygenase-1 haploinsufficiency reduces high fat diet-induced insulin resistance by affecting adipose macrophage infiltration in mice. PLoS One 7: e38626.
[15]
Wang Y, Kim KA, Kim JH, Sul HS (2006) Pref-1, a Preadipocyte Secreted Factor That Inhibits Adipogenesis. The Journal of Nutrition 136: 2953–2956.
[16]
Lazar MA (1999) PPARy in Adipocyte Differentiation. Journal of Animal Science 77: 16–22.
[17]
Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100: 328–341.
[18]
Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, et al. (2010) Regulation of Adipogenesis by Natural and Synthetic REV–ERB Ligands. Endocrinology 151: 3015–3025.
[19]
Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, et al. (2007) Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56: 2356–2370.
[20]
Thomas HE, Darwiche R, Corbett JA, Kay TW (2002) Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes 51: 311–316.
[21]
Vieira E, Marroqu？ L, Batista TM, Caballero-Garrido E, Carneiro EM, et al. (2012) The Clock Gene Rev-erbα Regulates Pancreatic Beta-Cell Function: Modulation by Leptin and High-Fat Diet. Endocrinology 153: 10.
